Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Bioorganic & Medicinal Chemistry Letters|June 1, 2013
The development of CNS-active LRRK2 inhibitors using property-directed optimisationMadeline E Kavanagh, Munikumar Reddy Doddareddy, Michael KassiouBioorganic & Medicinal Chemistry Letters|June 12, 2016
Spirooxindoles as novel 3D-fragment scaffolds: Synthesis and screening against CYP121 from M. tuberculosisHolly J Davis, Madeline E Kavanagh, Tudor Balan, et al.Biochemistry|February 8, 2017
Fragment Profiling Approach to Inhibitors of the Orphan M. tuberculosis P450 CYP144A1Madeline E Kavanagh, Jude Chenge, Azedine Zoufir, et al.Analytical Chemistry|August 15, 2017
Effect of DMSO on Protein Structure and Interactions Assessed by Collision-Induced Dissociation and UnfoldingDaniel S-H Chan, Madeline E Kavanagh, Kirsty J McLean, et al.Chemmedchem|July 20, 2016
Substrate Fragmentation for the Design of M. tuberculosis CYP121 InhibitorsMadeline E Kavanagh, Janine L Gray, Sophie H Gilbert, et al.European Journal of Medicinal Chemistry|March 21, 2015
Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammationLenka Munoz, Madeline E Kavanagh, Athena F Phoa, et al.Scientific Reports|May 27, 2016
Structural characterization of CYP144A1 - a cytochrome P450 enzyme expressed from alternative transcripts in Mycobacterium tuberculosisJude Chenge, Madeline E Kavanagh, Max D Driscoll, et al.Chemistry (Weinheim an Der Bergstrasse, Germany)|March 13, 2023
Structure Based Discovery of Inhibitors of CYP125 and CYP142 from Mycobacterium tuberculosisMona M Katariya, Matthew Snee, Richard B Tunnicliffe, et al.Journal of Medicinal Chemistry|March 23, 2016
Fragment-Based Approaches to the Development of Mycobacterium tuberculosis CYP121 InhibitorsMadeline E Kavanagh, Anthony G Coyne, Kirsty J McLean, et al.Nature Chemistry|September 10, 2021
A proteome-wide atlas of lysine-reactive chemistryMikail E Abbasov, Madeline E Kavanagh, Taka-Aki Ichu, et al.Pageof 2